

S0960-894X(96)00104-7

A Novel Class of Antagonists for Metabotropic Glutamate Receptors, 7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylates

Hirokazu Annoura,* Atsuko Fukunaga, Mayumi Uesugi Toshio Tatsuoka, and Yoshiko Horikawa

Suntory Institute for Biomedical Research 1-1-1, Wakayama-dai, Shimamoto-cho, Mishima-gun, Osaka 618, Japan

Abstract : 7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylates (**4a-c**), highly potent antagonists for a phospholipase C-linked metabotropic glutamate receptor, mGluR1, were synthesized through cyclopropanation onto 4-oxo-4H-1-benzopyran-2-carboxylates (**5a-c**) utilizing dimethyloxosulfonium methylid followed by treatment with hydroxylamine. Copyright © 1996 Elsevier Science Ltd

Metabotropic glutamate receptors (mGluRs) have been identified as a family of excitatory amino acid receptors coupled to intracellular signal transduction via G-proteins.¹ The recent molecular cloning studies^{1b,d,e,2} have revealed that mGluRs consist of eight subtypes, termed mGluR1 to mGluR8, which can be classified into three broad subgroups on the basis of sequence similarity, signal transduction mechanism, and agonist selectivity. The first group includes mGluR1 and mGluR5, both of which are positively coupled to phospholipase C and hydrolysis of phosphatidylinositol. The second group that consists of mGluR2 and mGluR3 is negatively coupled through adenylate cyclase to inhibition of c-AMP. The third group, including mGluR4, mGluR6, mGluR7 and mGluR8, is also linked to inhibition of c-AMP but the agonist selectivity markedly differs from that of the second group. Although selective agonists and antagonists for mGluRs have been reported such as trans-ACPD^{3a,b} (1), a series of 2-(carboxycyclopropyl)glycine (L-CCG-I)^{3c,d} 2a. its derivatives (DCG-IV^{3e,f} 2b and MCCG^{1f} 2c) and a series of 2-(carboxyphenyl)glycines^{1f,3g} [(S)-4CPG 3a and (RS)-MCPG 3b], it is still required to develop potent agonists and antagonists with selectivity for the different subtypes or subgroups to investigate the role of mGluRs in the mammalian central nervous system.⁴

In this communication, we report the synthesis of 7-(hydroxyimino)cyclopropa[b]chromen-lacarboxylates (**4a-c**), a structurally novel class of antagonists for a phospholipase C-linked metabotropic glutamate receptor such as mGluR1.



Chemistry

A survey of literature has revealed that a few methods⁵ involving carbene spieces for the construction of the cyclopropa[b]chromen-1a-carboxylate skeleton are reported. However, they are only limited to the 1-substituted cyclopropane derivatives and inapplicable to the synthesis of **4a-c**. After extensive experiments, we found that, upon treatment with Corey's dimethyloxosulfonium methylid⁶ generated from trimethylsulfoxonium iodide with NaOH in DMF, 4-oxo-4H-1-benzopyran-2-carboxylates⁷ (**5a-c**) underwent the cyclopropanation to produce the adducts **6a-c** in good yields.⁸

Scheme 1



The reactions of **6a-c** with hydroxylamine hydrochloride in pyridine gave **4a-c** accompanied by a small amounts of the geometric isomers on the oxime moiety (>20:<1) which could be easily separated by column chromatography over silica gel (hexane:ether=5:3). The stereochemistries of the oxime moiety of **4a-c** were determined to be E-configuration by comparison of their NMR data with those of the geometric Z-isomers. For instance, in the ¹H-NMR (270 MHz, CDCl₃) of **4a**,⁹ the signal of the C-7a methine proton appeared at δ 3.38 (dd, J=10.56 and 7.26 Hz) and this was shifted lower field than that of the geometric isomer¹⁰ (δ 2.85, dd, J=10.56 and 7.26 Hz) by anisotropic effect of the oxygen atom on the oxime moiety. Fortunately, recrystallization (hexane/ether) of the mixture gave only the E isomer **4a-c** in the yield shown in Scheme 1.

Results and Discussion

The effects of a series of the synthetic compounds 4a-c, 5a-c and 6a-c for mGluR1 were evaluated by measuring Ca^{2+} mobilization in response to 10 μ M glutamate in mGluR1 α -expressed CHO cells.^{2a,c} Consequently, 4a-c were found to be highly potent antagonists whose IC50 values were 23 μ M, 3 μ M and 10 uM. respectively. As shown in Figure 1, 4a-c inhibit in a dose-dependent manner and act as more powerful antagonists than the known 2-(carboxyphenyl)glycines [(S)-4CPG **3a**, IC50=200 µM; (RS)-MCPG **3b.** IC50=700 μ M] which are adopted as reference standard¹¹ for mGluR1 antagonists. In particular, the anilide derivative **4b** shows a 67-fold higher potency as compared with (S)-4CPG (**3a**). The compounds 4a-c were not partial agonists since no effects on basal Ca^{2+} mobilization was observed by themselves at the The characteristic feature of **4a-c** is the presence of a cyclopropane ring and an concentration 1 to 100 µM. oxime group that is essential for the antagonist activities since **5a-c** and **6a-c** did not show any effects. Furthermore, the ester 4a did not show any agonist and antagonist activities at ionotropic glutamate receptors [N-methyl-D-aspartate (NMDA), α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and kainate (KA) receptor subtypes] in *Xenopus* oocyte injected with rat $brain^{12}$ and the adenylate cyclase-linked mGluR2^{2b} at the concentration up to 100 μ M. A 100 μ M of **4a** completely inhibits on 10 μ M glutamateevolved Ca²⁺ mobilization in mGluR5-CHO cells.^{2d} Therefore, the oximes **4a-c** can be expected to be highly potent and selective antagonists for mGluR1 and mGluR5, the subtypes linked to the phosphatidyl-inositol hydrolysis, although further data are necessary to clarify their precise pharmacological profile.



In conclusion, we described a facile and practical method for the synthesis of 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylates (**4a-c**) which act as highly potent antagonists at the phospholipase C-linked receptor, mGluR1. To our knowledge, **4b** is the most potent antagonist for mGluR1 reported to date. The compounds **4a-c** would be useful tools to investigate the role of mGluRs in the mammalian central nervous system and their possible involvement in pathophysiological process. A more detailed data including the selectivity for each subtype and the structure-activity relationship of these compounds will be reported in due course.

Acknowledgement

We gratefully acknowledge to Professor Shigetada Nakanishi of School of Medicine of Kyoto University for providing mGluRs-expressed CHO cells. Dr. Shigeki Tamura is thanked for the assay of **4a** for ionotropic glutamate receptors.

References and Notes

- For reviews: (a) Schoepp, D.; Bockaert, J.; Sladeczek, F.; *Trends Pharmacol. Sci.* 1990, *11*, 1508;
 (b) Nakanishi, S.; *Science* 1992, 258, 597; (c) Schoepp, D. D.; Conn, P. J.; *Trends Pharmacol. Sci.* 1993, *14*, 13; (d) Nakanishi, S.; *Neuron* 1994, *13*, 1031; (e) Hollmann, M.; Heinemann, S.; *Annu. Rev. Neurosci.* 1994, *17*, 31; (f) Watkins, J.; Collingridge, G.; *Trends Pharmacol. Sci.* 1994, *15*, 333; (g) Knopfel, T.; Kuhn, R.; Allgeier, H.; *J. Med. Chem.* 1995, *38*, 1417.
- (a) Masu, M.; Tanabe, Y.; Tsuchida, K.; Shigemoto, R.; Nakanishi, S.; *Nature* 1991, 349, 760; (b) Tanabe, Y.; Masu, M.; Ishi, T.; Sigemoto, R.; Nakanishi, S.; *Neuron* 1992, 8, 169; (c) Aramori, I.; Nakanishi, S.; *Neuron* 1992, 8, 757; (d) Abe, T.; Sugihara, H.; Nawa, H.; Shigemoto, R.; Mizuno,

N.; Nakanishi, S.; J. Biol. Chem. 1992, 267, 13361.

- (a) Palmer, E.; Monaghan, D. T.; Cotman, C. W.; *Eur. J. Pharmacol.* 1989, *166*, 585; (b) Irving, A. J.; Schofield, J. G.; Watkins, J. C.; Sunter, D. C.; Collingridge, G. L.; *ibid.* 1990, *186*, 363; (c) Nakagawa, Y.; Saito, K.; Ishihara, T.; Ishida, M.; Shinozaki, H.; *ibid.* 1990, *184*, 205; (d) Ishida, M.; Akagi, H.; Shimamoto, K.; Ohfune, Y.; Shinozaki, H.; *Brain Res.* 1990, *537*, 311; (e) Ishida, M.; Saitoh, T.; Shimamoto, K.; Ohfune, Y.; Shinozaki, H.; *Br. J. Pharmacol.* 1993, *109*, 1169; (f) Ishida, M.; Saitoh, T.; Shinozaki, H.; *Neurosci. Lett.* 1993, *160*, 156; (g) Hayashi, Y.; Sekiyama, N.; Nakanishi, S.; Jane, D. E.; Sunter, D. C.; Birse, E. F.; Udvarhelyi, P. M.; Watkins, J. C.; *J. Neurosci.* 1994, *14*, 3370.
- 4. After we presented this study at AFMC International Medicinal Chemistry Symposium in Tokyo, September 3-8, 1995 (abstract p.79), Pellicciari et al. reported that 1-aminoindan-1,5- dicarboxylic acid, a confomationally constrained 2-(carboxyphenyl)glycine analogue, is a potent antagonist for mGluR1: Pellicciari, R.; Luneia, R.; Costantino, G.; Marinozzi, M.; Natalini, B.; Moroni, F.; Thomsen, C.; J. Med. Chem. 1995, 38, 3717.
- 5. (a) Dean, F. M.; Johnson, R. S.; J. Chem. Soc. Perkin Trans. 1 1981, 224; (b) Dicker, I. D.; Shipman, J.; Suschitzky, J. L.; *ibid.* 1984, 487.
- 6. Corey, E. J.; Chaykovsky, M.; J. Am. Chem. Soc. 1965, 87, 1353.
- Prepared from commercially available 4-oxo-4H-benzopyran-2-carboxylic acid: (a) Ellis, G. P.; Becket, G. J. P.; Shaw, D.; Wilson, H. K.; Vardey, C. J.; Skidmore, I. F.; J. Med. Chem. 1978, 21, 1120; (b) Davidson, D. N.; Kaye, P. T.; J. Chem. Soc. Perkin Trans. 2 1991, 927.
- 8. In contrast to our results, Suschitzky *et al.* reported that the similar reaction of the 4-oxo-4H-1benzopyran-2-carboxylate (I) bearing a hydroxy group at the benzene ring did not give the cyclopropanated products but yielded the benzofuran derivatives (IIa,b).^{5b}



- 9. 4a: ¹H-NMR (270 MHz, CDCl₃) δ: 1.35 (3H, t, J=7.26 Hz), 1.49 (1H, m), 2.05, (1H, dd, J=10.56 and 5.95 Hz), 3.38 (1H, dd, J=10.56 and 7.26 Hz), 4.28 (2H, q, J=7.26 Hz), 6.98 (1H, d, J=7.92Hz), 7.03 (1H, d, J=8.58 Hz), 7.32 (1H, m), 7.51 (1H, s, OH, exchangeable with D2O), 7.74 (1H, dd, J=7.92 and 1.32 Hz).
- ¹H-NMR (270 MHz, CDCl₃) δ: 1.35 (3H, t, J=7.26 Hz), 1.49 (1H, m), 1.84, (1H, dd, J=10.56 and 5.95 Hz), 2.85 (1H, dd, J=10.56 and 7.26 Hz), 4.32 (2H, q, J=7.26 Hz), 7.04 (1H, d, J=7.92Hz), 7.09 (1H, d, J=8.58 Hz), 7.37 (1H, m), 8.44 (1H, dd, J=7.92 and 1.32 Hz), 8.92 (1H, brs, OH, exchangeable with D2O).
- (S)-4CPG (3a) acts not only as an antagonist at mGluR1 but also as a week agonist at mGluR2. (RS)-MCPG (3b) is a nonselective antagonist for mGluR1 and mGluR2: See ref. 1f, 3g.
- 12. Sugiyama, Y.; Ito, I.; Hirono, C.; Nature 1987, 325, 531.

(Received in Japan 23 January 1996; accepted 19 February 1996)